NCT03551782 · Interventional trial
A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer
Overall registry status Completed
Phase 1
Conditions Castration-Resistant Prostatic Neoplasms
Delaware Valley sites
- Centers for Advanced Urology, LLC; d/b/a MidLantic Urology · Bala-Cynwyd, PA · Montgomery County
- Thomas Jefferson University · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory